Lupkynis (Voclosporin) Patent Expiration, LOE Window & CMS Spending
Lupkynis (Voclosporin) by Aurinia: FDA Orange Book core substance LOE 2027-10-17 (last listed 2037-12-07), 0 AB generics, $83.3M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Aurinia |
| FDA Application & Pathway | N213716 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2027-10-17 |
| Last Listed Patent or Exclusivity Date | 2037-12-07 |
| Orange Book Patents (*PED Extensions) | 3 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $83.3M |
| 2024 Medicare Part D Spend | $25.8M |
| 2024 Medicaid Spend | $57.5M |
| Reported Wholesale Price Change (CA SB 17) | 2 WAC filings (max 24.6% 2-yr change) |